Advertisements


New Drug Combinations Improve Survival in Lung Cancer

Combining expensive cancer immunotherapies with each other or with older drugs prolonged survival in lung cancer patients, two studies show. But the costs are high......»»

Category: smallbizSource: wsjApr 17th, 2018

Immune therapy doubles lung cancer survival rate

New drugs that trigger a patient’s immune system to kill malignant cells can greatly improve the survival rate of people with the most common type of lung cancer, a new study found. The study, published in the New England Journal of Medicine, found.....»»

Category: topSource: bizjournalsApr 17th, 2018

Merck shares rise after beating rivals" lung cancer results

In a fierce rivalry to prove cancer drug combinations work better for advanced.....»»

Category: topSource: marketwatchApr 16th, 2018

Lilly Reports Mixed Results from Late-Stage Cyramza Study

Lilly's (LLY) gastric cancer drug, Cyramza, meets primary endpoint of progression free survival in a phase III study in first-line advanced gastric cancer patients. However, it failed to improve overall survival. Eli Lil.....»»

Category: smallbizSource: nytDec 11th, 2017

Pfizer Lung Cancer Drug"s Overall Survival Data Unfavorable

Pfizer (PFE) announced final ov.....»»

Category: worldSource: nytSep 12th, 2017

AstraZeneca"s Lung Cancer Study Data Promising, Shares Spike

AstraZeneca, (AZN) releases data from a late-stage study on Imfinzi which showed that the new cancer drug led to superior progression-free survival to standard of care in lung cancer patients. AstraZeneca, plc A.....»»

Category: worldSource: nytSep 11th, 2017

Shares in AstraZeneca dive as key cancer drug trial fails

AstraZeneca said human trials of the drug Imfinzi failed to meet the goal of improving progression-free survival rates in patients with non-small cell lung cancer. &.....»»

Category: topSource: usatodayJul 27th, 2017

Merck Wins Big Against Rivals in Lung Cancer Study Survival Rates

Lung cancer may have just met a new standard of care. On top of that, it would be considered a new standard as a first line of care in lung cancer and longer overall survival rates......»»

Category: blogSource: 247wallstApr 17th, 2018

Brainstorm Health: Merck’s Lung Cancer Triumph, COPD and Women, Trump on Drug Prices

Brainstorm Health Daily: April 16, 2018 Hello and happy Monday, readers! This is Sy. New study results released Monday continue to cement drug giant Merck’s status as the force to be r.....»»

Category: europeSource: fortuneApr 16th, 2018

This Lung Cancer Drug Could Let Patients Forgo Chemo—And It’s Sending Merck’s Stock Soaring

Merck gained.....»»

Category: europeSource: fortuneApr 9th, 2018

Merck"s Keytruda helps lung cancer patients live longer in trial

(Reuters) - Merck & Co's blockbuster drug Keytruda helped previously untreated lung cancer patients live longer in a late-stage trial, potentially cementing its position as the dominant player in the lucrative lung cancer market......»»

Category: topSource: reutersApr 9th, 2018

Merck"s Keytruda meets main goal in pivotal lung cancer trial

(Reuters) - Merck & Co said on Monday a late-stage trial of its blockbuster cancer drug Keytruda met the main goal in helping previously untreated lung cancer patients live longer, sending its shares up 2.6 percent in premarket trade......»»

Category: topSource: reutersApr 9th, 2018

AstraZeneca"s Final Data From Key Lung Cancer Study Delayed

AstraZeneca's (AZN) final overall survival data from the pivotal phase III MYSTIC study on Imfinzi in first line lung cancer to be delayed in the second half of 2018. .....»»

Category: worldSource: nytMar 13th, 2018

AstraZeneca"s immunotherapy drug gets US FDA nod for lung cancer treatment

US FDA granted approval for expanded use of Imfinzi to treat non-small cell lung cancer patients.....»»

Category: topSource: business-standardFeb 17th, 2018

Bristol-Myers surges 5.6% on advanced lung cancer trial results, Q4 earnings

Bristol-Myers Squibb Co. shares surged 5.6% in premarket trade on Monday after the company reported positive results for its Opdivo and Yervoy cancer drug combination in a lat.....»»

Category: topSource: marketwatchFeb 5th, 2018

Merck & Co., Inc. (MRK) Stock Surges on Lung Cancer Drug Success

InvestorPlace - Stock Market News, Stock Advice & .....»»

Category: topSource: investorplaceJan 17th, 2018

Brainstorm Health: Universal Flu Vaccine, Merck Lung Cancer Drug, UnitedHealth Earnings

Brainstorm Health Daily: January 16, 2018 Hello, readers! This is Sy. Google parent Alphabet’s venture arm GV (formerly Google Ventures) is among the companies backing U.K. biotech Vaccitech, which has set out to achieve one.....»»

Category: europeSource: fortuneJan 16th, 2018

Merck leaps past rivals with latest lung cancer drug results

Smoking, which causes many lung cancer cases, has made advanced lung cancer a big market for pharmaceutical companies, and the competition has been fierce......»»

Category: topSource: marketwatchJan 16th, 2018

UPDATE: Merck shares jump 7% on news of positive results from lung cancer trial

Merck & Co. Inc. shares jumped almost 7% Tuesday, after the company announced positive results in a late-stage lung cancer trial. The New Jersey-based drug company said the Phase 3 trial of Keytruda in combination with pemetrexed and cisp.....»»

Category: topSource: marketwatchJan 16th, 2018

Merck Wins Big With Late-Stage Lung Cancer Drug Results

Merck saw its shares make a handy gain on Tuesday after it reported that a late-stage trial of Keytruda met its dual primary endpoints......»»

Category: blogSource: 247wallstJan 16th, 2018

UPDATE: Merck shares jump 5% on news of positive results from lung cancer trial

Merck & Co. Inc. shares jumped 5% premarket Tuesday, after the company announced positive results in a late-stage lung cancer trial. The New Jersey-based drug.....»»

Category: topSource: marketwatchJan 16th, 2018